key: cord-0299334-5m967chx
authors: Dogan, Alan; Dabkowski, Katherine; von Recum, Horst
title: Leveraging Affinity Interactions to Prolong Drug Delivery of Protein Therapeutics
date: 2020-12-04
journal: bioRxiv
DOI: 10.1101/2020.12.03.410621
sha: 652f3be23760c35024e82cec4e00ebe38af3dce7
doc_id: 299334
cord_uid: 5m967chx

While peptide and protein therapeutics have made tremendous advances in clinical treatments over the past few decades, they have been largely hindered by their ability to be effectively delivered to patients. While bolus parenteral injections have become standard clinical practice, they are insufficient to treat diseases that require sustained, local release of therapeutics. Cyclodextrin-based polymers (pCD) have been utilized as a platform to extend the local delivery of small-molecule hydrophobic drugs by leveraging hydrophobic-driven thermodynamic interactions between pCD and payload to extend its release, which has seen success both in vitro and in vivo. Herein, we proposed the novel synthesis of protein-polymer conjugates that are capped with a “high affinity” adamantane. Using bovine serum albumin as a model protein, and anti-interleukin 10 monoclonal antibodies as a functional example, we outline the synthesis of novel protein-polymer conjugates that, when coupled with cyclodextrin delivery platforms, can maintain a sustained release of up to 65 days without largely sacrificing protein structure/function which has significant clinical applications in local antibody-based treatments for immune diseases, cancers, and diabetes. Graphical Abstract

Protein and peptide therapeutics have emerged in the past few decades as a major branch of modern 28

pharmacology. Due to their modulability, high specificity, and low off-target activity, protein therapeutics 29 have been utilized to treat diseases including cancers, genetic disorders, autoimmunity/inflammatory Rifampicin and other smaller therapeutics like RNA, the delivery proteins, to our knowledge, has never 70 been achieved due to their large molecular weights and hydrophilic nature 21, 22 . 71 72

Recently, our group has shown that conjugating polymer chains capped with "high affinity" groups can 73

increase the overall conjugate's affinity towards pCD polymers 23, 24 . Briefly, by taking advantage of the 74 strong interactions between adamantane (Ad) hydrocarbons and beta-cyclodextrin (KD ~ 5 x 10 -4 M), we 75 have shown that the affinity between pCD and the drugs rifampicin and rapamycin can be increased by 76

conjugating polymer tethers end-capped with adamantane groups (referred to as polymer-Ad). The drug-77

Ad conjugates exhibited a higher loading capacity and an extended window of release in pCD 78 hydrogels 23,24 , thereby suggesting that by manipulating the KD between the payload and pCD matrix, we 79 are able to modulate delivery and loading. 80 81

As protein and peptide therapeutics now constitute the current, and possibly future, direction of 82 pharmaceuticals, we proposed to apply the idea of modulating affinity to hydrophilic payloads, like 83 proteins, so that they can take advantage of the "affinity-driven" loading and release kinetics common to 84 pCD hydrogels. Many current protein delivery systems, such as PLGA hydrogels, are single use, difficult 85

to clinically deliver, and may degrade into unwanted byproducts, many of which can negatively impact 86 the overall therapeutic efficiency of the payload 25 . pCD hydrogels, on the other hand, do not degrade and 87

can be reused and refilled with drugs after initial administration by nearby, bolus injection, making it 88 ideal for long-term therapeutic treatments 26,27 . 89 90

Herein, we used bovine serum albumin (BSA) as a model protein, and monoclonal antibodies (mAb) as a 91

functional example to show that proteins can be delivered from pCD hydrogels by increasing the protein's 92 affinity for the system through the conjugation of polymer-Ad groups (Figure 1) To synthesize adamantane-capped PEG (Ad-PEG5000-Mal), a 1:1 (w/w) ratio of adamantane carbonyl 118 chloride and maleimide-PEG5000-hydroxyl was dissolved in anhydrous chloroform (5 mL chloroform per 119 1 g mixture), according to a previous protocol 28 . Equal molar amounts of triethylamine to PEG was then 120 added dropwise and the solution was allowed to react for 24 hrs. at room temperature (RT) under 121 agitation (Figure 2a) . Once reacted, the product was precipitated with diethyl ether three times (using 122 half of the total volume of chloroform) and solvent was removed in vacuum at 25 O C overnight (ON). As 123 pCD is a covalently bonded polymer network with closely-packed monomer units, PEG5000 was selected 124

for adamantane conjugation as its estimated hydrodynamic radius (~2 nm) was predicted to sufficiently 125 "space out" the adamantane groups from the hydrophobic, interior of folded proteins (3-14 nm). This was 126 done to help ensure adamantane groups were available for complexation within cyclodextrin's interior. 127 128

Protein-PEG5000-Ad conjugates were synthesized with sulfhydryl-reactive crosslinker chemistry. Protein 129 samples (Bovine Serum Albumin, BSA, or monoclonal antibody, mAb) were incubated with 10x molar 130 excess TCEP (tris(2-carboxyethyl)phosphine) slurry for 1 hr at RT on an end-over-end mixer. Once 131 disulfide bonds were reduced, a variable molar excess (2x, 4x, 8x) of Ad-PEG5000-Mal was added to the 132 protein samples, and were allowed to react 4 hrs at RT (or ON at 4 o C) (Figure 2b) . The protein-polymer 133 conjugates were then dialyzed for 48 hrs. (MWCO = 14 kD). In this study, BSA-PEG5000-Ad and mAb-134 PEG5000-Ad were investigated. 135 Nuclear magnetic resonance (NMR) was used to verify successful conjugation during synthesis steps. All 144 spectra of presented chemical species were recorded by Bruker 300 MHz NMR system (Bruker, 145

Germany) in DMSO-D6 or Chloroform-D solvent, as indicated. 146 147

2.4 Rate of Hydrolysis for (Ad-PEG5000-Mal) species 148 149

10 mg of Adamantane-PEG5000-Mal was dissolved in 10 mL of DMSO-D6 and incubated to 37 o C, 150 agitated at 100 rmp. 600 µL aliquots were sampled at designated intervals and 1 H-NMR spectra were 151 obtained. Percent hydrolysis was determined by comparing the integral of the "hydrolysis alcohol peak" 152 at δ = 6.1 ppm and a fixed peak at δ = 4. Synthesis of Ad-PEG5000-Mal was confirmed via 1 H-NMR. Confirmation of Ad conjugation to 242 maleimide-PEG5000-hydroxyl was observed as the coexistence of adamantane's hydrocarbon (-CH2) peaks 243 at δ =1.7-1.9 ppm and PEG's repeating backbone (-CH2-) peak at δ =3.6 ppm. Reaction yield was 244 determined by comparing the peak integrals of adamantane (δ =1.7-1.9 ppm; 16 hydrogens) and the last 245 carbon of PEG (δ = 4.2 ppm; 2 hydrogens), and a range of 73-96% conversion (n=2 batches) was 246 observed (Figure 3) . 247 3.2 PEG-Adamantane "tethers" remain stable for up to 40 days 254 255

As Ad-PEG5000-Mal contains an ester group prone to hydrolysis, the stability of the chemical species was 256 observed over time via 1 H-NMR. The integral of the terminal hydroxyl peak (-OH) at δ = 6.1 ppm was 257 compared to a constant PEG (-CH2-) peak at δ = 4.2 ppm, and a percent species of hydrolysis was 258 obtained. Over time, the integral of the terminal hydroxyl peak increased until it equaled half of the 259 integral of the δ = 4.2 ppm, indicating 100% species hydrolysis. We found that at around 40 days, the 260 adamantane is completely dissociated from the PEG linker, which is most likely attributed to the partially-261 solubility of Ad-PEG5000-Mal (Figure 4) . Hydrolysis was confirmed to have zero-order kinetics. 262 hydrolysis peak at δ = 6.1 ppm and a reference peak at δ = 4.2 ppm (-CH2-) c) At species percentage was 265 quantitively obtained from hydrolysis peak δ = 6.1 ppm 266 267

3.3 PEG-Ad 'tethers' successfully conjugated to reduced proteins 268 269

To ensure maleimide-sulfhydryl chemistry was successfully taking place, nonreducing SDS-PAGE gels 270

were used to quantify the molecular weight of our BSA and mAb protein-polymer conjugates (Figure 5) . 271 An increase in molecular weight was observed for all protein-polymer species, and estimated conjugation 272 ratio (ECR) of each species was obtained by the following equation Affinity between our protein-polymer conjugates and β-CD was tested using surface plasmon resonance 285 (SPR). Unmodified protein species had characteristically low affinity for β-CD, while an increase in Ad-286 PEG5000 conjugation corresponded to an increased affinity (decreased KD). However, we found that as the 287 number of 'affinity' groups were increased, we were unable to obtain low Chi 2 value curve fittings, as 288 indicated in Table 1 . KD values were determined from steady state affinity equation curve fitting 289

according to standards set in Biacore's evaluation software. 290 291 Table 1 βCD / mAb 0.0001443 * -21.9 βCD / mAb-(PEG5000-Ad)2 8.755E-10 * -52.9 βCD / mAb-(PEG5000-Ad)4

3.012E-11 -54.1 βCD / mAb-(PEG5000-Ad)8 4.515E-13 -70.4 295 3.5 PEG-adamantane conjugation to BSA greatly increases loading capacity into pCD, regardless of form 296 297

BSA-(PEG5000-Ad)2 was observed to have superior loading over both BSA-(PEG5000-Ad)4 and BSA-298 (PEG5000-Ad)8 ( Figure 6 ). As BSA-(PEG5000-Ad)4/8 had comparable loading we predict that both species 299

were able to maximize the number of inclusion complexes formed with pCD hydrogels, however the 300 increase in PEG-Ad groups sterically hindered their ability to diffuse deeply into pCD. While MPs were 301 observed to have slightly higher loading of BSA, and BSA-(PEG5000-Ad)2, there were no significant 302 differences in loading between SRPL and MPs in BSA-(PEG5000-Ad)4/8. 303 3.6 Protein-polymer conjugates can be delivered for up to 65 days in pCD polymers 308 309 We observed that all BSA conjugates released for a significantly longer time (45-65 days) than BSA 310 controls (1-2 days). While all groups experienced a 'burst' release within days 1-4, a prolonged "affinity" 311 release was observed after day 6 (Figure 7b and 7d) . BSA, which lacks the ability to form inclusion 312 complexes with pCD, was observed to only exhibit a brief, diffusion-based release. However, the 313 extended release observed by BSA conjugates were most likely the combination of diffusion, 'affinity' 314 from adamantane groups complexing with pCD, and subsequent hydrolysis of adamantane groups. While 315 MP pCD was found to have more favorable loading capabilities, we found that SRPL was able to sustain 316 release of its payload over a longer period of time. All release curves were found to be statistically 317 significant from one another (one-way ANOVA with Tukey, p<0.05), with the exception of BSA-318 (PEG5000-Ad)4 and BSA-(PEG5000-Ad)8 in both MP and SRPL pCD. Comparing cumulative release with 319 our total release values in Figure 6 , around 18% of the loaded drug was never released from the pCD 320

MPs while 20% was never released from pCD SRPL. 321 322 Figure 7 : Cumulative drug release curves for BSA-polymer conjugates from a) pCD MPs b) pCD MPs 323 zoomed in on release days 9-65 and c) pCD SRPL d) pCD SRPL zoomed in on release days 9-65. All 324 datasets were found to be statistically significant from one another (one-way ANOVA with Tukey, 325 p<0.05), except BSA 4 and BSA 8 curves in both MP and SRPL trials. 326 327 3.7 All mAb-polymer conjugates maintained at least 70% of antigen-recognition ability 328 329

As past literature has noted that mAb-polymer conjugates are at risk of losing antigen specificity after 330 alteration, we utilized a modified ELISA to quantify these changes in structure/function. After modifying 331 the detection mAb of an ELISA sandwich assay, we found that given a constant saturation of ligand 332

(human interleukin-10 [hIL-10], 500 pg/ml), a decrease in overall detection occurred, which we attributed 333

to loss of antigen-recognition. Normalizing these values to unmodified positive controls, we were able to 334 obtain a quantitative value for the mAb-analog's ability to recognize its respective antigen (Figure 8) . 335 While all groups were statistically different from the positive controls, one-way ANOVA test revealed 336 that the groups were not statistically different from one another (p=0.151). 337

Cooperative Biotin Binding by Streptavidin

Cyclodextrin-adamantanecarboxylate inclusion 475 complexes: Studies of the variation in cavity size

Affinity-Based Drug Delivery

Thermomechanical properties, 479 antibiotic release, and bioactivity of a sterilized cyclodextrin drug delivery system

Localized and targeted delivery of NSAIDs for treatment of 482 inflammation: A review

Emerging technologies for long-term antimicrobial device 484 coatings: advantages and limitations

Using Affinity To Provide Long-Term Delivery of 486

Antiangiogenic Drugs in Cancer Therapy

Self-Assembled Cationic β-Cyclodextrin Nanostructures for siRNA Delivery

Molecular encapsulation of rifampicin as an inclusion complex of hydroxypropyl-β-490 cyclodextrin: Design; characterization and in vitro dissolution

Engineering selective molecular tethers to enhance suboptimal drug 496 properties

Hydrogels in drug delivery: Progress and challenges

Serum biomolecules unable to 500 compete with drug refilling into cyclodextrin polymers regardless of the form

Bone Cement Enables Postimplantation Drug Refilling, Broadens Range of Compatible 504

Supramolecular hydrogels cross-linked by preassembled host-guest PEG cross-506 linkers resist excessive, ultrafast, and non-resting cyclic compression

Injectable liquid polymers extend the delivery of corticosteroids for the 509 treatment of osteoarthritis

Affinity-based polymers provide long-term 511 immunotherapeutic drug delivery across particle size ranges optimal for macrophage targeting

Preserves Sirolimus Activity and Local Persistence for Antifibrotic Delivery over the Time Course 515 of Wound Healing

Cyclodextrin-based device coatings for 517 affinity-based release of antibiotics

Antibody-Drug Conjugates: Possibilities and Challenges. Avicenna 519

Antibody conjugates: From heterogeneous populations to 521 defined reagents

Local release from affinity-based polymers increases urethral 523 concentration of the stem cell chemokine CCL7 in rats

 Figure 8 : Quantitative estimation of mAb (anti-IL10) structure/function after PEG5000-Ad conjugation. 339 Positive controls (according to MabTag protocol) were assumed to have 100% antigen recognition. 340 341 342 4. Discussions 343 344 As pCD has been traditionally used for the prolonged delivery of small-molecule, hydrophobic drugs by 345 complexing with drug ligands in a 1:1 model, this work demonstrates a novel approach for protein-346 therapeutic delivery by leveraging the thermodynamic interactions between pCD polymers and protein-347 polymer conjugates. We successfully synthesized a PEG-Adamantane 'tether' group, which was shown to 348 remain unhydrolyzed over the span of 40 days (Figures 3 and 4) . We then observed that these high-349 affinity 'tether' groups were able to be successfully conjugate to reduced peptides via maleimide-350 sulfhydryl chemistry (Figure 5) , and that the addition of PEG-Ad groups to peptides significantly 351 increased their affinity for pCD, as shown in decreased KD values between protein-polymer conjugates 352 and β-CD (Table 1) . This increase in affinity, as correlated in previous studies, yielded significant gains 353 in loading capabilities in pCD polymers ( Figure 6 ) and greatly enhanced drug release kinetics (Figure 7) . 354Compared to unmodified BSA, which was delivered at a limited capacity for only 1 day, our BSA-355conjugates were able to load in pCD polymers at significantly higher amounts and exhibited a profoundly 356 longer window of delivery (Figures 6 and 7) .It is well known that PEGylation and modification of mAbs and other structure-dependent therapeutics 359 decreases their ability to bind to their respective ligand in vitro and in vivo 33 . We sought to investigate the 360 impact PEG5000-Ad conjugation has on mAb antigen-recognition in vitro by modifying a sandwich ELISA 361 assay by conjugating the polymer groups to the detection antibody. We found this modified method 362 produced detectable differences in antigen-recognition capabilities between unmodified and modified 363anti-IL-10 mAbs, and while some mAb function was lost, ~70% specificity was retained between all 364 protein-polymer groups (Figure 8 ).

When measuring affinity, we found that SPR was unable to achieve statistically significant steady-state 367 curve fitting with chemical species with over two potential complexing domains, namely BSA-(PEG5000-368Ad)4/8 and mAb-(PEG5000-Ad)4/8 ( Table 1) . We hypothesize that because SPR measures 'affinity' between 369 a monolayered "host" and mobile "ligand" it was unable to accurately detect higher-degree complexation. 370 Nonetheless, based on drug loading and drug release kinetics, we can still conclude that an increase in 371 complexation "high-affinity" groups increased the species' overall affinity for β-CD (Figure 6 and 7) . 372Regardless, it is also important to note that KD values decreased nonlinearly ( Table 1) , suggesting that as 373 more PEG-Ad groups were added, the molecule was unlikely to maximize interactions with pCD (i.e. not 374all Ad groups were able to complex with a CD molecule). 375 376Drug loading and delivery results suggest that there may be an upper limit to how many inclusion 377 complexes a single drug payload can form in pCD. Given the similar performance of BSA-(PEG5000-Ad)4 378and BSA-(PEG5000-Ad)8 in both MP and SRPL pCD ( Figure 6 and 7) , we hypothesize that despite BSA-379 (PEG5000-Ad)8's average of 5.9 'affinity groups' per molecule, not all of these groups are being utilized to 380 increase thermodynamic interactions, perhaps due to the limited distancing of Ad from the protein itself. 381Most likely, only two to four groups are actually available for docking in pCD, while the other PEG-Ad 382 groups only add to molecular steric hinderance, which may explain the decreased overall loading 383 efficiency in BSA-(PEG5000-Ad)4/8 ( Figure 6 ). However, we did observe that the increased 'affinity' 384 groups decreased the overall 'burst' release that occurred both in MP and SRPL pCD (Figure 7) . 385 386 pCD structure appeared to not have a large impact on drug loading capabilities, however SRPL was 387 observed to have an extended window of delivery to up to 65 days, as opposed to 45-58 days in MP pCD 388 (Figure 7) . We predict this difference in delivery stems from topology differences between MP spheres 389 and SRPL 'branches' -permeable branching architecture allowed for increased interactions between 390 payload and pCD. Furthermore, we observed a notable increase in optical opacity in SRPL samples after 391 BSA-conjugate loading, which may have been a product of PEG-Ad complexation with pCD. 392 393The idea of 'multiplexing' interactions between a chemical species and cyclodextrin inclusion complexes 394have consistently shown to enhance loading and delivery of small-molecule therapeutics, however, to our 395 knowledge, this study is the first study that showed that multiplexing thermodynamic interactions can 396 help deliver higher molecular weight payloads (>1 kD) 23,24 . While the exact mechanism of loading and 397 release has not been studied, we suspect that our drug release profiles are the integrated result of 398 thermodynamic interactions, diffusion, and aqueous solubility, which is impacted by our 'affinity-group' 399 adamantane hydrolysis from PEG. 400 401While this study specifically examined protein-polymer conjugates synthesized via maleimide-sulfhydryl 402 chemistry, alternative bioconjugation techniques, such as lysine-based conjugation, can be utilized to 403 generate similar species 34 . For example, the ester bond connecting Ad-PEG can be replaced with an amide 404 for more stable tethers or acid/base reactive tethers for controlled and triggered delivery, respectively. In 405 addition, altering PEG-linker lengths may impact the capacity for pCD binding -our attempt to account 406 for this in our experimental design (choosing PEG5000 due to its hydrodynamic radius) seems to have 407 sufficiently distanced our adamantane groups from the protein to promote inclusion in cyclodextrins. 408 409BSA was used as a model drug for this study due to its low cost and ease of detection, however our 410 outlined synthesis and pCD delivery platform can be applied to extend the drug delivery of any peptide or 411 protein therapeutic with modifiable residues. Especially in situations where local, sustained delivery of 412 protein therapeutics is ideal for positive treatment outcomes -such as the delivery of anti-VEGF 413